Vesalius Cardiovascular Inc.

Vesalius Cardiovascular is a Canadian medical device company founded in 2016 in Vancouver, Canada. The company specializes in designing and developing biomedical devices for the treatment of cardiovascular disease, specifically mitral valve regurgitation (MR). We are preclinical. Our devices will be introduced percutaneously (transfemoral/transseptal) to the heart, eliminating the need for open heart surgery and the related risks. The procedure can be performed by a Cardiovascular Interventionalist (Cardiologist or Cardiac Surgeon). Vesalius Cardiovascular is the result of several years of intensive private research and investigation. The inventor behind Vesalius Cardiovascular is Dr. Peter Skarsgard, a Vancouver-based Cardiac Surgeon, and Head of the Division of Cardiovascular Surgery at Vancouver General Hospital. Our Advisory Board includes some of BC’s most prominent clinicians, including: - Peter Skarsgard (MD), Cardiac Surgeon and Head of Cardiovascular Surgery at VGH - Christopher Durkin (MD), Anaesthesiologist with advanced expertise in 3D echo for intracardiac structural disease - Jacqueline Saw (MD), Interventional Cardiologist with specialized expertise in percutaneous device delivery and structural heart intervention Vesalius Cardiovascular is currently developing Calla, a biomedical device that can be introduced percutaneously (transfemoral/transseptal) to the heart, for the treatment of degenerative MR (due to mitral valve prolapse), the most common variety of MR. The principles of surgical mitral valve repair are utilized, but sternotomy, heart-lung bypass, and cardiac arrest - components of an open heart operation - are not required